Related Experiment Videos
Tumor-specific T-bodies: towards clinical application
1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. lieshhar@weizmann.weizmann.ac.il
Cancer Immunology, Immunotherapy : CII
|January 22, 1998
Summary
T-bodies combine T cells and antibodies to target solid tumors. These engineered T cells can recognize and destroy cancer cells while sparing healthy ones, offering a promising cancer therapy approach.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Antibodies are limited in solid tumor penetration.
- T cells possess inherent tumor-destroying capabilities.
- A novel approach is needed to leverage T cell effector functions for solid tumor treatment.
Purpose of the Study:
- To introduce and evaluate the T-body approach for cancer therapy.
- To assess the efficacy and specificity of T-bodies in targeting tumor cells.
- To explore the potential of T-bodies in overcoming limitations of current antibody therapies.
Main Methods:
- Engineering T cells to express chimeric receptors (T-bodies).
- Chimeric receptors combine antibody-derived Fv/scFv recognition with T cell signaling.
- Testing T-bodies in vitro and in vivo models for tumor cell killing and specificity.
Main Results:
- T-bodies demonstrated specific recognition and killing of target tumor cells.
- The T-body approach functions independently of MHC presentation.
- Engineered T cells showed minimal bystander cytotoxicity against normal cells.
- Successful targeting of hapten-modified and tumor cells observed in model systems.
Conclusions:
- T-bodies represent a viable strategy for solid tumor treatment by combining antibody specificity with T cell effector functions.
- This approach offers potential for targeted cancer therapy with reduced off-target effects.
- Further research is warranted to optimize T-body persistence, homing, and in vivo reactivation for clinical application.